Psoriatic arthritis (PsA) is a form of inflammatory arthritis which occurs in patients with psoriasis. Recent surveys of psoriasis patients in the United States and Europe suggest that PsA occurs in 11% to 30% of all patients with psoriasis.1,2 The likelihood of development of PsA may in part be due to the severity of psoriasis.1 It is possible that the disease prevalence may be underestimated if it is mistakenly classified as another, more common form of arthritis, such as osteoarthritis or rheumatoid arthritis, or if it is present but not clinically evident to the patient.3 The clinical features, pathogenesis and management of PsA have been reviewed in journals, and in Psoriasis Forum.4–10
Get full access to this article
View all access options for this article.
References
1.
GelfandJ., GladmanD., MeaseP.Epidemiology of psoriatic arthritis in the United States population. J Am Acad Dermatol in press: 2005.
2.
SalonenS.The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,900 members of European psoriasis patient associations (poster) in Spring Symposium of the European Academy of Dermatology and Venereology.2003. Malta.
3.
OffidaniA., CelliniA., ValeriG.Subclinical joint involvement in psoriasis: magnetic resonance imaging and X-ray findings. Acta Derm Venereol.1998; 78: 463–5.
4.
GladmanD., AntoniC., MeaseP.Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis.2005; 64(suppl 2): ii14–ii17.
5.
HelliwellP.S., WrightV.Psoriatic arthritis: clinical features. In Rheumatology; KlippelJ., and DieppeP., Editors. 2000. Mosby Co: St. Louis, Mo. p. 6.21.1–6.21.8.
6.
BruceI.Psoriatic arthritis: clinical features. In Rheumatology, HochbergM. Editors. 2003. Mosby: Philadelphia, Pa. p. 1241–1252.
7.
GladmanD., RahmanP.Psoriatic arthritis. In Kelly's Textbook of Rheumatology; RuddyS., Editors. 2001. WB Saunders Co: Philadelphia, Pa. p. 1071–1079.
8.
HelliwellP., TaylorW.Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis.2005; 64(suppl 2): ii3–ii8.
NashP., CleggD.O.Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis.2005; 64(Suppl 2): ii74–ii77.
11.
RappS.R., FeldmanS.R., ExumM.L.Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol.1999; 41: 401–7.
12.
MeaseP., MenterA.Quality of life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective. Journal of American Academy of Dermatology in press: 2006.
13.
LangleyR., KruegerG., GriffithsC.Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis.2005; 64(suppl 2): ii18–ii23.
KirwanJ.R.Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J Rheumatol.1999; 26: 720–5.
16.
StrandV., SharpJ.T.Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned?Arthritis Rheum.2003; 48: 21–34.
17.
ScottD.L., PugnerK., KaarelaK.The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford).2000; 39: 122–32.
18.
PincusT., SokkaT.Quantitative target values of predictors of mortality in rheumatoid arthritis as possible goals for therapeutic interventions: an alternative approach to remission or ACR20 responses?J Rheumatol.2001; 28: 1723–34.
19.
PincusT., FerraccioliG., SokkaT.Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford).2002; 41: 1346–56.
20.
ChungC., SokkaT., BrooksR.Patient questionnaires are the most significant predictors of mortality over 5, 10, and 15 years in 210 patients with rheumatoid arthritis even when joint count, radiograph and laboratory studies are available. Arthritis Rheum.2005; 52(suppl 9): S122.
21.
MichaudK., WolfeF.Reduced mortality among RA patients treated with anti-TNF therapy and methotrexate. Arthritis Rheum.2005; 52(Suppl 9): S145.
22.
van HalmV., NurmohamedM., TwiskJ.W.Anti-rheumatic drugs are associated with reduction of cardiovascular risk in patients with rheumatoid arthritis. Arthritis Rheum.2005; 52(suppl 9): S704.
23.
FinckhA., ChoiH.K., WolfeF.Progression of radiographic joint damage in different eras. Trends towards milder disease in Rheumatoid Arthritis are attributable to improved therapy. Ann Rheum Dis.2006 (in press).
24.
MeaseP.TNF alpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis.2004; 63: 755–8.
25.
RitchlinC.T., Haas-SmithS.A., LiP.Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest.2003; 111: 821–31.
26.
VealeD., RitchlinC., FitzGeraldO.Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis.2005; 65(suppl 2): ii26–ii29.
27.
BaetenD., KruithofE., De RyckeL.Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther.2005; 7: R359–69.
28.
De RyckeL., VandoorenB., KruithofE.Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondyloarthropathy. Arthritis Rheum.2005; 52: 2146–58.
29.
KruithofE., BaetenD., De RyckeL.Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther.2005; 7: R569–80.
30.
EjbjergB.J., VestergaardA., JacobsenS.Conventional radiography requires a MRI-estimated bone volume loss of 20% to 30% to allow certain detection of bone erosions in rheumatoid arthritis metacarpophalangeal joints. Arthritis Res Ther.2006; 8: R59.
31.
OstergaardM., HansenM., StoltenbergM.New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthritis Rheum.2003; 48: 2128–31.
32.
OstergaardM., SzkudlarekM.Imaging in rheumatoid arthritis—why MRI and ultrasonography can no longer be ignored. Scand J Rheumatol.2003; 32: 63–73.
33.
LandeweR.B., BoersM., VerhoevenA.C.COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum.2002; 46: 347–56.
34.
van der HeijdeD.M., van LeeuwenM.A., van RielP.L.Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol.1995; 22: 1792–6.
35.
McQueenF.M., BentonN., CrabbeJ.What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using X rays and magnetic resonance imaging over the first two years of disease. Ann Rheum Dis.2001; 60: 859–68.
36.
ScottD.L.Radiological progression in established rheumatoid arthritis. J Rheumatol Suppl.2004; 69: 55–65.
37.
SharpJ.T., LidskyM.D., CollinsL.C.Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum.1971; 14: 706–20.
38.
WolfeF., SharpJ.T.Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum.1998; 41: 1571–82.
39.
ScottD.L., SymmonsD.P., CoultonB.L.Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet.1987; 1: 1108–11.
40.
GladmanD.D., RitchlinC., HelliwellP.S.Psoriatic arthritis clinical registries and genomics. Ann Rheum Dis.2005; 64 Suppl 2: ii103–5.
41.
GladmanD.D., FarewellV.T., NadeauC.Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol.1995; 22: 675–9.
42.
WongK., GladmanD.D., HustedJ.Mortality studies in psoriatic arthritis: results from a single outpatient clinic. Causes and risk of death. Arthritis Rheum.1997; 40: 1868–72.
43.
WrightV.Psoriatic arthritis; a comparative study of rheumatoid arthritis, psoriasis, and arthritis associated with psoriasis. AMA Arch Derm.1959; 80: 27–35.
OryP., GladmanD.D., MeaseP.Psoriatic arthritis and imaging. Ann Rheum Dis.2005; 64(suppl 2): ii55–ii57.
46.
OryP.A.Radiography in the assessment of musculoskeletal conditions. Best Pract Res Clin Rheumatol.2003; 17: 495–512.
47.
van der HeijdeD., KavanaughA., BeutlerA.Infliximab inhibits progression of radiographic damage in patients with active psoriatic damage in patients with active psoriatic arthritis: Results from IMPACT 2 trial. Ann Rheum Dis.2005; 64(suppl 3): 109.
48.
KleckerR.J., WeissmanB.N.Imaging features of psoriatic arthritis and Reiter's syndrome. Semin Musculoskelet Radiol.2003; 7: 115–26.
49.
BennettD.L., OhashiK., El-KhouryG.Y.Spondyloarthropathies: ankylosing spondylitis and psoriatic arthritis. Radiol Clin North Am.2004; 42: 121–34.
50.
GenantH.K.Methods of assessing radiographic change in rheumatoid arthritis. Am J Med.1983; 75: 35–47.
51.
SharpJ.T.Radiographic evaluation of the course of articular disease. Clin Rheum Dis.1983; 9: 541–57.
52.
van der HeijdeD., SimonL., SmolenJ.How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum.2002; 47: 215–8.
53.
BrowerA.C.Radiographic assessment of disease progression in rheumatoid arthritis. Rheum Dis Clin North Am.1991. 17: 471–85.
54.
BrowerA.C.Rheumatoid arthritis-Imaging. In Rheumatology, KlippelJ., and DieppeP., Editors. 1998. Mosby: London. p. 5.1–5.8.
55.
van der HeijdeD.How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol.2000; 27: 261–3.
56.
GenantH.K., JiangY., PeterfyC.Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum.1998; 41: 1583–90.
57.
SiglerJ.W., BluhmG.B., DuncanH.Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med.1974; 80: 21–6.
58.
RauR., HerbornG., KargerT.Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy. A controlled study. Arthritis Rheum.1991; 34: 1236–44.
59.
WeinblattM.E., PolissonR., BlotnerS.D.The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum.1993; 36: 613–9.
60.
SharpJ.T., StrandV., LeungH.Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum.2000; 43: 495–505.
61.
AntoniC., KruegerG.G., de VlamK.Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis.2005; 64: 1150–7.
62.
MeaseP., GladmanD., RitchlinC.Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum.2005; 52: 3279–3289.
63.
MeaseP., KivitzA., BurchF.Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum.2004; 50: 2264–2272.
64.
JiangY., GenantH.K., WattI.A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum.2000; 43: 1001–9.
65.
KremerJ.M., DougadosM., EmeryP.Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum.2005; 52: 2263–71.
66.
MeaseP.J., GoffeB.S., MetzJ.Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet.2000; 356: 385–90.
67.
AntoniC.E., KavanaughA., KirkhamB.Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum.2005; 52: 1227–36.
68.
MeaseP.J., KivitzA.J., BurchF.X.Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol.2006; 33: 712–721.
69.
RauR., WassenbergS., HerbornG.Identification of radiologic healing phenomena in patients with rheumatoid arthritis. J Rheumatol.2001; 28: 2608–15.
70.
Abu-ShakraM., GladmanD.D., ThorneJ.C.Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol.1995; 22: 241–5.
71.
MeaseP.J., van der HeijdeD.Joint damage in psoriatic arthritis: how is it assessed and can it be prevented?Int J Adv Rheumatol.2006; 4(2): 38–48.
72.
JarrettS., O'ConnorP.P.C.First evidence of structural benefit from a bisphosphonate, zoledronic acid in rheumatoid arthritis. Ann Rheum Dis.2004; 63(suppl 1): 58.
73.
CohenS., McCLungM., LewieckiE.AMG 162 administration every 6 months causes rapid and sustained decreases in bone turnover in postmenopausal women with low bone mineral density (BMD). Arthritis and Rheum.2004; 50(suppl 9): S438.
